Hit enter to search or ESC to close

News

Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson’s and Alzheimer’s

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the United States Patent and Trademark Office (USPTO) has granted a new patent (No. 11,155,547) to Alterity. The composition of matter patent, entitled “Compounds for and Methods of Treating Diseases”, underwent ...

Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022. The presentation will be accessible on the Alterity website under News on Monday, January ...

First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial

Initiation of Phase 2 Clinical Trial Expected in CY Q1 2022 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has authorized Alterity’s Phase 2 clinical trial for ATH434 ...

Alterity Therapeutics to Participate in Two Upcoming Investor Conferences

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that David Stamler, M.D., Chief Executive Officer will participate in two upcoming virtual investor events: MST Financial Lifesciences & Biotech Fourm Wednesday, November 24th at 5:20 p.m. PST (U.S.) / Thursday, ...

Chairman’s Address 2021 Annual General Meeting

I am pleased to present my Chairman’s address at this year’s Annual General Meeting. For the second year in a row, we do this under unique circumstances, and we appreciate the involvement of our shareholders and our corporate partners in today’s virtual setting. FY 21 was a significant year for Alterity and for me personally ...

Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced a poster presentation and accompanying video were delivered at the American Autonomic Society 32nd Annual Internation Symposium on the Autonomic Nervous System. The poster, entitled, Cardiovascular safety and pharmacokinetics of ATH434, ...
Senior male researcher carrying out scientific research

Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases

Colorectal impairment reversed in a preclinical model of Parkinson’s Disease   ATH434 presents a novel mechanism of action for the treatment of neurodegenerative diseases Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced the publication of two preclinical studies demonstrating ...

Appendix 4C – Q1 FY22 Quarterly Cash Flow Report

Highlights: New details on ATH34 Phase 2 clinical trial released. Data from bioMUSE presented at International Parkinson and Movement Disorder Society Congress. Expanded intellectual property portfolio positions future opportunities. Cash balance as of 30 September 2021 of A$41.3M. Quarterly operating cash outflow of $4.9M as expected and in-line with clinical trial activity. Alterity Therapeutics Limited ...

Receive news from Alterity Therapeutics